Search for: "APOTEX INC. v. SANOFI-AVENTIS"
Results 1 - 20
of 54
Sort by Relevance
|
Sort by Date
21 Jun 2016, 4:00 am
Absent more definitive consistent instruction from the Federal Court of Appeal, or direct SCC pronouncement on the proper approach, patent drafters are still advised to keep their promises to a minimum to avoid disclosure challenges regarding sound prediction. _________________________ [1] Eli Lilly v Hospira 2016 FC 47 (Barnes) [2] Gilead v Idenix 2015 FC 1156 at para 381 (Annis), under appeal A-483-15, adopting earlier reasoning of Astra v Apotex 2014 FC 638… [read post]
14 May 2015, 4:00 am
In Eli Lilly Canada Inc. v. [read post]
26 Apr 2015, 4:30 am
Music and movie firms back website-blocking in Singapore http://t.co/VyYvVZsIN0 -> Goebbels' estate sues Random House for diary royalties http://t.co/1PDCxZpeuA -> Companies' 'fears are real' with Chinese cyber law http://t.co/4DwKwMLVEx -> European privacy watchdogs join forces to probe Facebook – Oneindia http://t.co/e6M4Q2OEcC -> Computer and Internet Law Weekly Updates for 2015-04-18: blogged: Computer and Internet Law Weekly Updates for…… [read post]
18 Jan 2015, 9:06 pm
LLC; Aventis Pharma S.A.; Sanofi • Defendants: Apotex Corp.; Apotex Inc. [read post]
21 Nov 2014, 4:00 am
Justice Gleason found Sanofi-Aventis 2007 was “dispositive” and it was an abuse for the brand to re-litigate obviousness in case2: “That issue was the same in both cases and arose directly from the patent, itself. [read post]
30 Oct 2014, 8:21 am
Apotex Inc., et al. [read post]
26 Jul 2014, 9:14 pm
Methods of medical treatment came under scrutiny of the US Supreme Court in Mayo Collaborative Services v Prometheus Laboratories, Inc and the Australian High Court in Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (see High Court Rules Methods of Medical Treatment Patent-Eligible). [read post]
25 Jul 2013, 11:43 am
By Dennis Crouch Mylan Inc. v. [read post]
19 Apr 2012, 10:00 pm
The post points out two major caveats in the decision. 4) Patent Docs: Marine Polymer Technologies, Inc. v. [read post]
19 Apr 2012, 10:00 pm
The post points out two major caveats in the decision. 4) Patent Docs: Marine Polymer Technologies, Inc. v. [read post]
9 Nov 2011, 9:59 pm
By Donald Zuhn -- In an appeal decided last month, the Federal Circuit reversed a decision by the District Court for the Southern District of New York awarding prejudgment interest to Plaintiffs-Appellees Sanofi-Aventis, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership ("Sanofi"); affirmed the District Court's denial of a motion for leave to file a supplemental answer, affirmative… [read post]
18 Oct 2011, 8:31 am
” Sanofi- Aventis v. [read post]
10 Aug 2011, 4:30 am
”: a note on Neurim (The SPC blog) France: The end of the reform on the appearance of generic drugs and IPR (Class 46) Spain: A SHED OF LIGHT IN THE DARK: First Spanish decision admitting post-grant claim limitations under article 138.3 of CPE 2000: Sanofi-Aventis v. [read post]
3 Aug 2011, 3:31 am
Application fee increases by a whopping 19.4% (or almost $300K) (FDA Law Blog) US: Life sciences venture funding up 37% in second quarter (Patent Docs) Products Arava (Leflunomide) – Australia: FCA ‘evergreens’ Arava: Sanofi-Aventis Australia v Apotex (Patentology) Cambia (Diclofenac) – US: Nautilus files patent infringement complaint against Edict Pharmaceuticals in response to Para IV certification filing (Patent Docs) Cenestin… [read post]
29 Jun 2011, 3:34 am
Apotex Inc. et al. [read post]
25 May 2011, 8:52 pm
Therasense, Inc. v. [read post]
18 Feb 2011, 11:47 am
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
8 Feb 2011, 10:51 pm
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New Jersey: Court precludes… [read post]
29 Dec 2010, 2:57 am
Highlights this week included: CAFC: Broad scope of statutory subject matter: Prometheus Laboratories, Inc. v. [read post]
6 Oct 2010, 4:22 am
Sandoz, Inc. et al (Docket Report) [read post]
